(Q35211001)

7 August 2017

1 reference

title

Chemotherapeutic strategies for renal cell carcinoma (English)

1 reference

7 August 2017

1 reference

Matthew I Milowsky

1

1 reference

PubMed ID

12953758

7 August 2017

David M Nanus

series ordinal

2

1 reference

7 August 2017

1 August 2003

1 reference

Urologic Clinics of North America

7 August 2017

1 reference

7 August 2017

30

1 reference

7 August 2017

3

1 reference

7 August 2017

601-9, x

1 reference

7 August 2017

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Rising incidence of renal cell cancer in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Obesity, hypertension, and the risk of kidney cancer in men

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

1 reference

7 January 2021

Adjuvant Therapy for Adenocarcinoma of the Kidney: Present Position and Prospects1

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

1 reference

7 January 2021

Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Papillary renal cell carcinoma: a clinical, radiologic, and pathologic study of 34 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Chromophobe cell carcinoma of the kidney. A clinicopathologic study of 21 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Chromophobe cell renal carcinoma: clinicopathological features of 50 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

A phase II study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Recombinant interferon-alpha with or without vinblastine in metastatic renal carcinoma. Results of a randomised phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma. A phase I-II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma. A Hoosier Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Interferon-alpha, 5-FU and prednisone in metastatic renal cell carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Interferon-alpha and 5-fluorouracil therapy in patients with metastatic renal cell cancer: an open multicenter trial. The Japanese Study Group Against Renal Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

A phase II study of high-dose cimetidine and the combination 5-fluorouracil, interferon alpha-2A, and leucovorin in advanced renal cell adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Vitamin A derivatives in the prevention and treatment of human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

13-cis-Retinoic Acid and Interferon -2a: Effective Combination. Therapy for Advanced Squamous Cell Carcinoma of the Skin

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

13-cis-Retinoic Acid Plus Interferon -2a: Highly Active Systemic Theraphy for Squamous Cell Carcinoma of the Cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Liposome-associated retinoic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Interaction of liposome-associated all-trans-retinoic acid with squamous carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900031-4

7 January 2021

10.1016/S0094-0143(03)00031-4

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

12953758